This document is a summary of the European Public Assessment Report authorised(EPAR) for Humenza. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to
Pandemic influenza vaccine (H1N1) (split virion, inactivated, adjuvanted)
reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Humenza.
been inactivated (killed). Humenza contains a flu strain called A/California/7/2009
What is Humenza used for?
Humenza is a vaccine to protect against ‘pandemic’ flu. It should only be used for the influenza A (H1N1)Medicinalflu pandemic that was officially declared by the World Health Organization on 11 June 2009. A flu pandemic happens when a new strain of flu virus appears that can spread easily from person to
person because people have no immunity (protection) against it. A pandemic can affect most countries and regions around the world. Humenza is given according to official recommendations.
The vaccine can only be obtained with a prescription.